Global Radiopharmaceutical Theragnostic Market By Clinical Trial Phase (Phase I, Phase II, Phase III); By Application (Thyroid cancer, Brain cancer, Lymphoma, Others); By Route of Administration (Oral, Intravenous, Interstitial); By End-Users (Hospitals and Clinics, Pharmaceutical Companies, Research Centers, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029